Early Changes of the Standardized Uptake Values (SUV<sub>max</sub>) Predict the Efficacy of Everolimus-Exemestane in Patients with Hormone Receptor-Positive Metastatic Breast Cancer

Early Changes of the Standardized Uptake Values (SUV<sub>max</sub>) Predict the Efficacy of Everolimus-Exemestane in Patients with Hormone Receptor-Positive Metastatic Breast Cancer

<i>Background:</i> The mTORC1 inhibitor everolimus has been approved in combination with the aromatase inhibitor exemestane for the treatment of hormone receptor-positive (HR+) human epidermal growth factor receptor 2-negative (HER2−) metastatic breast cancer (HR+ mBC) progressing on pri...

Full description

Bibliographic Details
Main Authors: Marianna Sirico, Ottavia Bernocchi, Navid Sobhani, Fabiola Giudici, Silvia P. Corona, Claudio Vernieri, Federico Nichetti, Maria Rosa Cappelletti, Manuela Milani, Carla Strina, Valeria Cervoni, Giuseppina Barbieri, Nicoletta Ziglioli, Martina Dester, Giulia Valeria Bianchi, Filippo De Braud, Daniele Generali
Format: Article
Language:English
Published: MDPI AG 2020-11-01
Series:Cancers
Subjects:
metastatic breast cancer
everolimus
<sup>18</sup>F-FDG PET/CT
∆SUV%
predictive biomarker
Online Access:https://www.mdpi.com/2072-6694/12/11/3314

Internet

https://www.mdpi.com/2072-6694/12/11/3314

Similar Items